Amgen, Inc. (AMGN)
443.37
+0.53
(+0.12%)
USD |
NASDAQ |
Sep 03, 15:14
Amgen Cash from Investing (Quarterly) : -569.00M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -569.00M |
| March 31, 2026 | -716.00M |
| December 31, 2025 | -693.00M |
| September 30, 2025 | -414.00M |
| June 30, 2025 | -389.00M |
| March 31, 2025 | -447.00M |
| December 31, 2024 | -402.00M |
| September 30, 2024 | -210.00M |
| June 30, 2024 | -217.00M |
| March 31, 2024 | -217.00M |
| December 31, 2023 | -27.09B |
| September 30, 2023 | -262.00M |
| June 30, 2023 | -211.00M |
| March 31, 2023 | 1.358B |
| December 31, 2022 | -3.473B |
| September 30, 2022 | -267.00M |
| June 30, 2022 | -2.193B |
| March 31, 2022 | -111.00M |
| December 31, 2021 | -230.00M |
| September 30, 2021 | 73.00M |
| June 30, 2021 | 1.209B |
| March 31, 2021 | -319.00M |
| December 31, 2020 | -1.384B |
| September 30, 2020 | -1.628B |
| June 30, 2020 | -2.159B |
| Date | Value |
|---|---|
| March 31, 2020 | -230.00M |
| December 31, 2019 | -5.963B |
| September 30, 2019 | 5.372B |
| June 30, 2019 | 2.745B |
| March 31, 2019 | 3.555B |
| December 31, 2018 | -4.637B |
| September 30, 2018 | 1.132B |
| June 30, 2018 | 2.938B |
| March 31, 2018 | 14.91B |
| December 31, 2017 | -78.00M |
| September 30, 2017 | -1.976B |
| June 30, 2017 | -1.813B |
| March 31, 2017 | -157.00M |
| December 31, 2016 | -1.222B |
| September 30, 2016 | -2.389B |
| June 30, 2016 | -657.00M |
| March 31, 2016 | -4.39B |
| December 31, 2015 | -233.00M |
| September 30, 2015 | -2.003B |
| June 30, 2015 | -2.359B |
| March 31, 2015 | -952.00M |
| December 31, 2014 | 374.00M |
| September 30, 2014 | -2.903B |
| June 30, 2014 | -2.458B |
| March 31, 2014 | -765.00M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Gilead Sciences, Inc. | -10.35B |
| Regeneron Pharmaceuticals, Inc. | -92.70M |
| AbbVie, Inc. | -1.197B |
| Biogen, Inc. | -3.839B |
| Vertex Pharmaceuticals, Inc. | -45.80M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 4.002B |
| Cash from Financing (Quarterly) | -1.482B |
| Free Cash Flow | 10.18B |
| Free Cash Flow Per Share (Quarterly) | 6.414 |
| Free Cash Flow to Equity (Quarterly) | 3.508B |
| Free Cash Flow to Firm (Quarterly) | 4.077B |
| Free Cash Flow Yield | 4.22% |